Special promotion: Enjoy a 10% discount on Elabscience recombinant proteins through September 30, 2025.
Promo code: ELABPQ3
No additional discounts available during this period.
Protein Tag: C-Fc
Uniprot: O00548
Accession: O00548
Background: Delta-like protein 1(DLL1) , also known as Delta1 , a single-pass type I membrane protein which contains one DSL domain and eight EGF-like domains , acts as a ligand for Notch receptors , and positively regulates T-cell development. DLL1 is proteolytically processed in a similar manner to the Notch receptor , and it has been speculated to participate in bidirectional signaling. The proteolytic processing of DLL1 helps achieve an asymmetry in Notch signaling in initially equivalent myogenic cells and helps sustain the balance between differentiation and self-renewal. Interactions between DLL1 and Notch in trans activate the Notch pathway , whereas DLL1 binding to Notch in cis inhibits Notch signaling. DLL1 undergoes proteolytic processing in its extracellular domain by ADAM10. It had been demonstrated that DLL1 represents a substrate for several other members of the ADAM family. In co-transfected cells , DLL1 is constitutively cleaved by ADAM12 , and the N-terminal fragment of DLL1 is released to medium. ADAM12-mediated cleavage of DLL1 is cell density-dependent , takes place in cis orientation , and does not require the presence of the cytoplasmic domain of ADAM12. Full-length DLL1 , but not its N-or C-terminal proteolytic fragment , co-immunoprecipitates with ADAM12. By using a Notch reporter construct , we show that DLL1 processing by ADAM12 increases Notch signaling in a cell-autonomous manner. Furthermore , ADAM9 and ADAM17 have the ability to process DLL1. In contrast , ADAM15 does not cleave DLL1 , although the two proteins still co-immunoprecipitate with each other. During fetal development , DLL1 is an essential Notch ligand in the vascular endothelium of large arteries to activate Notch1 and maintain arterial identity. DLL1-Notch signaling was required for VEGF receptor expression in fetal arteries.
Bio Acitivity: Not validated for activity
Sequence: Ser22-Gly540
Purity: > 90% as determined by reducing SDS-PAGE.
Formulation: Lyophilized from a 0.2 μm filtered solution in PBS with 5% Trehalose and 5% Mannitol.
Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.5 mg/mL. Concentration is measured by UV-Vis.
Endotoxin: < 1.0 EU/mg of the protein as determined by the LAL method.
Calculated MW: 81.9 kDa
Observed MW: 90 kDa
Deutsch
English
